Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutically targeting tumor microenvironment–mediated drug resistance in estrogen receptor–positive breast cancer
Kevin Shee, Wei Yang, John W. Hinds, et al.
The Journal of Experimental Medicine (2018) Vol. 215, Iss. 3, pp. 895-910
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Drug resistance in cancer: mechanisms and tackling strategies
Tanweer Haider, Vikas Pandey, Nagma Banjare, et al.
Pharmacological Reports (2020) Vol. 72, Iss. 5, pp. 1125-1151
Closed Access | Times Cited: 216
circFBXW7 Inhibits Malignant Progression by Sponging miR-197-3p and Encoding a 185-aa Protein in Triple-Negative Breast Cancer
Feng Ye, Guanfeng Gao, Yutian Zou, et al.
Molecular Therapy — Nucleic Acids (2019) Vol. 18, pp. 88-98
Open Access | Times Cited: 213
Tumor microenvironment promotes breast cancer chemoresistance
Umar Mehraj, Abid Hamid Dar, Nissar Ahmad Wani, et al.
Cancer Chemotherapy and Pharmacology (2021) Vol. 87, Iss. 2, pp. 147-158
Closed Access | Times Cited: 213
High-Throughput Screen Identifies Host and Microbiota Regulators of Intestinal Barrier Function
Inna Grosheva, Danping Zheng, Maayan Levy, et al.
Gastroenterology (2020) Vol. 159, Iss. 5, pp. 1807-1823
Closed Access | Times Cited: 139
Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies
Mohamed El‐Tanani, Syed Arman Rabbani, Rasha Babiker, et al.
Cancer Letters (2024) Vol. 591, pp. 216894-216894
Open Access | Times Cited: 46
Nuclear receptors: recent drug discovery for cancer therapies
Linjie Zhao, Shengtao Zhou, Jan-Ακε Gustafsson
Endocrine Reviews (2019)
Open Access | Times Cited: 142
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Pingping Mao, Ofir Cohen, Kailey J. Kowalski, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 22, pp. 5974-5989
Open Access | Times Cited: 130
Astrocytic trans-Differentiation Completes a Multicellular Paracrine Feedback Loop Required for Medulloblastoma Tumor Growth
Maojin Yao, Patrick Ventura, Ying Jiang, et al.
Cell (2020) Vol. 180, Iss. 3, pp. 502-520.e19
Open Access | Times Cited: 122
FGF/FGFR signaling pathway involved resistance in various cancer types
Yangyang Zhou, Cheng‐Yu Wu, Guangrong Lu, et al.
Journal of Cancer (2020) Vol. 11, Iss. 8, pp. 2000-2007
Open Access | Times Cited: 93
Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance
Lucy Ireland, Ainhoa Mielgo
Frontiers in Cell and Developmental Biology (2018) Vol. 6
Open Access | Times Cited: 92
Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling
Harriet R. Ferguson, Michael P. Smith, Chiara Francavilla
Cells (2021) Vol. 10, Iss. 5, pp. 1201-1201
Open Access | Times Cited: 92
Combination therapy based on nano codelivery for overcoming cancer drug resistance
Hairui Wang, Yongzhuo Huang
Medicine in Drug Discovery (2020) Vol. 6, pp. 100024-100024
Open Access | Times Cited: 90
Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer
Teodora Costea, Oana Vlad, Luminita Claudia Miclea, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 2, pp. 401-401
Open Access | Times Cited: 75
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role
Maxwell R. Lloyd, Seth A. Wander, Erika Hamilton, et al.
Therapeutic Advances in Medical Oncology (2022) Vol. 14
Open Access | Times Cited: 62
FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance
Jakub Szymczyk, Katarzyna Dominika Sluzalska, Izabela Materla, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5796-5796
Open Access | Times Cited: 61
Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value
Alessio Ardizzone, Valentina Bova, Giovanna Casili, et al.
Cells (2023) Vol. 12, Iss. 7, pp. 1002-1002
Open Access | Times Cited: 30
Ligand-based active targeting strategies for cancer theranostics
Anupriya Bandyopadhyay, Tuyelee Das, Samapika Nandy, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 396, Iss. 12, pp. 3417-3441
Closed Access | Times Cited: 25
Extracellular matrix-mediated regulation of cancer stem cells and chemoresistance
Yazmin Brown, Susan Hua, Pradeep S. Tanwar
The International Journal of Biochemistry & Cell Biology (2019) Vol. 109, pp. 90-104
Closed Access | Times Cited: 75
Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities
Maxwell R. Lloyd, Laura M. Spring, Aditya Bardia, et al.
Clinical Cancer Research (2021) Vol. 28, Iss. 5, pp. 821-830
Open Access | Times Cited: 52
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression
Benedetta Pellegrino, Zuzana Hlavata, Cristina Migali, et al.
Molecular Diagnosis & Therapy (2021) Vol. 25, Iss. 4, pp. 409-424
Open Access | Times Cited: 49
Heterogeneity and tumoral origin of medulloblastoma in the single-cell era
Hui Sheng, Haotai Li, Han Zeng, et al.
Oncogene (2024) Vol. 43, Iss. 12, pp. 839-850
Open Access | Times Cited: 8
FGF2 induces breast cancer growth through ligand‐independent activation and recruitment of ERα and PRBΔ4 isoform to MYC regulatory sequences
Sebastián Giulianelli, Marina Riggio, Tomás Guillardoy, et al.
International Journal of Cancer (2019) Vol. 145, Iss. 7, pp. 1874-1888
Open Access | Times Cited: 54
FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors
Alberto Servetto, Luigi Formisano, Carlos L. Arteaga
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021) Vol. 1876, Iss. 2, pp. 188595-188595
Open Access | Times Cited: 33
Cancer Stem Cells and the Tumor Microenvironment in Tumor Drug Resistance
Qiuzhi Gao, Yixiang Zhan, Li Sun, et al.
Stem Cell Reviews and Reports (2023) Vol. 19, Iss. 7, pp. 2141-2154
Closed Access | Times Cited: 15
The Role of Glypican-1 in the Tumour Microenvironment
Maria E. Lund, Douglas Houghton Campbell, Bradley J. Walsh
Advances in experimental medicine and biology (2020), pp. 163-176
Closed Access | Times Cited: 33
Page 1 - Next Page

Scroll to top